SCHEMBL2747792

SCHEMBL2747792

CCc1cc(CO)cc(C)n1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.39
NOS2 P35228 1/20 0.39
ACHE P22303 1/20 0.34
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
GAA P10253 1/20 0.33
MAPK1 P28482 1/20 0.33
HSD17B10 Q99714 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
ABL1 P00519 1/20 0.33
THRB P10828 1/20 0.32
KDM5B Q9UGL1 1/20 0.32
RECQL P46063 1/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
ABCG2 Q9UNQ0 1/20 0.31
EDNRB P24530 1/20 0.31
EDNRA P25101 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11030024 0.87 ACHE (0.42) ACHEKMT2AMEN1GAAMAPK1
SCHEMBL5898465 0.87 NOS3 (0.40) NOS3NOS2ACHEHSD17B10KDM5B
SCHEMBL7129717 0.85 NOS3 (0.43) NOS3NOS2KMT2ANPC1RAB9A
SCHEMBL17932864 0.83 NPC1 (0.37) NOS3NOS2KMT2AMEN1GAA
SCHEMBL20072601 0.83 ACHE (0.42) NOS3NOS2ACHEHSD17B10KDM5B
SCHEMBL377724 0.82 ACHE (0.43) ACHEKMT2AMEN1GAAMAPK1
SCHEMBL18501666 0.79 NOS3 (0.44) NOS3NOS2NPC1RAB9AKDM5B
SCHEMBL16346209 0.78 RECQL (0.47) NOS3NOS2ACHEKMT2AGAA
Hydrochloric Acid SCHEMBL18489384 0.78 NOS3 (0.42) NOS3NOS2GAANPC1RAB9A
SCHEMBL16345715 0.78 NOS2 (0.57) NOS3NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016128529-A1 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2016-08-18 WO disclosed
US-8697732-B2 Pyridine derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2014-04-15 US disclosed
US-20120195930-A1 NOVEL PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2012-08-02 US disclosed
US-8178562-B2 Pyridine derivatives ACTELION PHARMACEUTICALS, LTD. (CH) 2012-05-15 US disclosed
CN-101370805-B Pyridine derivatives ACTELION PHARMACEUTICALS LTD 2011-04-27 CN disclosed
EP-1979345-B1 NOVEL PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-11-04 EP disclosed
CN-101370805-A Novel pyridine derivatives ACTELION PHARMACEUTICALS LTD (CH) 2009-02-18 CN disclosed
US-20090005421-A1 Novel Pyridine Derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2009-01-01 US disclosed
EP-1979345-A2 NOVEL PYRIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2008-10-15 EP disclosed
WO-2007086001-A2 NOVEL PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005421-A1 Novel Pyridine Derivatives NFATC1, TPMT, CD47 NOS3 1902/4885NOS2 1762/4885ACHE 4202/4885
US-20120195930-A1 NOVEL PYRIDINE DERIVATIVES NFATC1, TPMT, CD47 NOS3 1902/4885NOS2 1762/4885ACHE 4202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.